相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma
Apoorva Ambavane et al.
IMMUNOTHERAPY (2020)
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J. Motzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies
Bo Huang et al.
ANNALS OF INTERNAL MEDICINE (2020)
Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Time to deterioration in quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214
D. Cella et al.
ANNALS OF ONCOLOGY (2020)
Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer
Praful Ravi et al.
CANCER JOURNAL (2020)
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J. Motzer et al.
CANCER CELL (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma
Charlene M. Mantia et al.
CANCER (2019)
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M. Regan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
David Cella et al.
LANCET ONCOLOGY (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian Rini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Alternate sunitinib schedules in patients with metastatic renal cell carcinoma
S. Kalra et al.
ANNALS OF ONCOLOGY (2015)
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
T. Powles et al.
ANNALS OF ONCOLOGY (2013)
Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma
Michael K. Wong et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
